Topiramate exposure in early pregnancy is linked to higher rates of major malformations and more specifically to increased risk of oral clefts, with risk rising at higher doses.
A systematic review examines neurodevelopmental outcomes in children prenatally exposed to antiepileptic drugs.
Data from a Nordic register-based study observed a significant increase in risk for autism spectrum disorder and intellectual disability in children with prenatal exposure to topiramate.
Multiple studies have associated first trimester exposure to topiramate with increased risk of oral clefts.
For women with bipolar disorder, choosing whether to maintain or discontinue treatment with a mood stabilizer during pregnancy is challenging. This is a process which requires careful and thoughtful consideration, weighing the risk of adverse [...]
There have long been concerns regarding the safety of the anticonvulsant valproic acid (Depakote) during pregnancy. Â Back in 2009, the American Academy of Neurology and American Epilepsy Society recommended against the use of valproic acid [...]
EURAP is an international registry for antiepileptic drugs and pregnancy. Â At its inception in 1999, it included only European countries but EURAP has grown and now includes 42 countries from Europe, Australia, Asia, South America. [...]
Topiramate (TPM, marketed as Topamax) is an antiepileptic drug which is also used for migraine prophylaxis, weight loss, and, less commonly, as a mood stabilizer. Â Over the last few years we have seen several studies [...]
Many of the newer antiepileptic drugs (AEDs) have uses beyond the treatment of epilepsy. Â Topiramate (marketed as a Topamax), in addition to its use for the treatment of epilepsy, is now being prescribed to reproductive [...]
Topiramate (TPM, marketed as Topamax) is an antiepileptic drug which is also used for migraine prophylaxis, weight loss, and, less commonly, as a mood stabilizer. Â Over the last few years we have seen several studies [...]
